Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

被引：44

作者：

Kastritis, Efstathios ^{[1
]}

Kyrtsonis, Marie-Christine ^{[1
]}

Hadjiharissi, Evdoxia ^{[1
]}

Symeonidis, Argyris ^{[1
]}

Michalis, Evridiki ^{[1
]}

Repoussis, Panagiotis ^{[1
]}

Tsatalas, Constantinos ^{[1
]}

Michael, Michael ^{[1
]}

Sioni, Anastasia ^{[1
]}

Kartasis, Zafiris ^{[1
]}

Stefanoudaki, Ekaterini ^{[1
]}

Voulgarelis, Michail ^{[1
]}

Delimpasi, Sossana ^{[1
]}

Gavriatopoulou, Maria ^{[1
]}

Koulieris, Efstathios ^{[1
]}

Gika, Dimitra ^{[1
]}

Zomas, Athanasios ^{[1
]}

Roussou, Paraskevi ^{[1
]}

Anagnostopoulos, Nikolaos ^{[1
]}

Economopoulos, Theophanis ^{[1
]}

Terpos, Evangelos ^{[1
]}

Zervas, Konstantinos ^{[1
]}

Dimopoulos, Meletios A. ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Dept Clin Therapeut, Athens 11528, Greece

来源：

LEUKEMIA RESEARCH | 2010年 / 34卷 / 10期

关键词：

Lymphoplasmatic lymphoma; Prognosis; Age; Cause-specific survival; High risk; CONSENSUS PANEL RECOMMENDATIONS; CELL LYMPHOMA; WORKSHOP; SURVIVAL; CRITERIA; THERAPY; DISEASE; UPDATE; INDEX; MODEL;

D O I：

10.1016/j.leukres.2010.04.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The recently proposed, ISSWM staging system for symptomatic patients with WM was based on patients treated with alkylating agents and nucleoside analogs and has not been externally validated nor has been validated for cause-specific survival (CSS). We independently validated ISSWM both for overall survival (OS) and for CSS and assessed whether addition of elevated serum LDH may add to the strength of ISSWM in 335 patients treated upfront mainly with alkylating agents (43%), and rituximab-based therapies (47%). ISSWM could discriminate three groups with significantly different OS and CSS (p < 0.01 for both). High serum LDH was predictive of shorter OS and CSS (p < 0.01). The combination of high risk according to ISSWM and elevated serum LDH identified a subset of patients for whom innovative treatment approaches are needed. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：1340 / 1343

页数：4

共 24 条

[1] Prognostic value of serum β2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment [J].

Anagnostopoulos, Athanasios ;

Zervas, Konstantinos ;

Kyrtsonis, Marie Christine ;

Symeonidis, Argyris ;

Gika, Dimitra ;

Bourantas, Konstantinos ;

Zomas, Athanasios ;

Anagnostopoulos, Nikolaos ;

Pangalis, Gerasimos ;

Dimopoulos, Meletios Athanasios .

CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (03) :205-209

[2] Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003) [J].

Dhodapkar, MV ;

Jacobson, JL ;

Gertz, MA ;

Crowley, JJ ;

Barlogie, B .

SEMINARS IN ONCOLOGY, 2003, 30 (02) :220-225

[3] Diagnosis and management of Waldenstrom's macroglobulinemia [J].

Dimopoulos, MA ;

Kyle, RA ;

Anagnostopoulos, A ;

Treon, SP .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) :1564-1577

[4] HIGH SERUM LACTATE-DEHYDROGENASE LEVEL AS A MARKER FOR DRUG-RESISTANCE AND SHORT SURVIVAL IN MULTIPLE-MYELOMA [J].

DIMOPOULOS, MA ;

BARLOGIE, B ;

SMITH, TL ;

ALEXANIAN, R .

ANNALS OF INTERNAL MEDICINE, 1991, 115 (12) :931-935

[5] The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens [J].

Dimopoulos, Meletios Athanasios ;

Kastritis, Efstathios ;

Delimpassi, Sossana ;

Zomas, Athanasios ;

Kyrtsonis, Marie Christine ;

Zervas, Konstantinos .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (09) :1420-1422

[6] PROGNOSTIC FACTORS IN WALDENSTROM MACROGLOBULINEMIA - A REPORT OF 167 CASES [J].

FACON, T ;

BROUILLARD, M ;

DUHAMEL, A ;

MOREL, P ;

SIMON, M ;

JOUET, JP ;

BAUTERS, F ;

FENAUX, P .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1553-1558

[7] Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia [J].

Ghobrial, IM ;

Fonseca, R ;

Gertz, MA ;

Plevak, MF ;

Larson, DR ;

Therneau, TM ;

Wolf, RC ;

Hoffmann, RJ ;

Lust, JA ;

Witzig, TE ;

Lacy, MQ ;

Dispenzieri, A ;

Rajkumar, SV ;

Zeldenrust, SR ;

Greipp, PR ;

Kyle, RA .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 (02) :158-164

[8] STUDY OF PROGNOSIS IN WALDENSTROMS MACROGLOBULINEMIA - A PROPOSAL FOR A SIMPLE BINARY CLASSIFICATION WITH CLINICAL AND INVESTIGATIONAL UTILITY [J].

GOBBI, PG ;

BETTINI, R ;

MONTECUCCO, C ;

CAVANNA, L ;

MORANDI, S ;

PIERESCA, C ;

MERLINI, G ;

BERTOLONI, D ;

GRIGNANI, G ;

POZZETTI, U ;

CAPORALI, R ;

ASCARI, E .

BLOOD, 1994, 83 (10) :2939-2945

[9] A prognostic score for advanced Hodgkin's disease [J].

Hasenclever, D ;

Diehl, V .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1506-1514

[10] Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols [J].

Hoering, Antje ;

Crowley, John ;

Shaughnessy, John D., Jr. ;

Hollmig, Klaus ;

Alsayed, Yazan ;

Szymonifka, Jackie ;

Waheed, Sarah ;

Nair, Bijay ;

Van Rhee, Frits ;

Anaissie, Elias ;

Barlogie, Bart .

BLOOD, 2009, 114 (07) :1299-1305

← 1 2 3 →